- Home
- NXRT vs MDXG Comparison
NXRT vs MDXG Comparison
Compare NXRT & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXRT
- MDXG
- Stock Information
- Founded
- NXRT 2014
- MDXG 2006
- Country
- NXRT United States
- MDXG United States
- Employees
- NXRT N/A
- MDXG N/A
- Industry
- NXRT Real Estate Investment Trusts
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- NXRT Real Estate
- MDXG Health Care
- Exchange
- NXRT Nasdaq
- MDXG Nasdaq
- Market Cap
- NXRT 1.0B
- MDXG 1.3B
- IPO Year
- NXRT N/A
- MDXG N/A
- Fundamental
- Price
- NXRT $39.26
- MDXG $8.57
- Analyst Decision
- NXRT Buy
- MDXG Strong Buy
- Analyst Count
- NXRT 5
- MDXG 5
- Target Price
- NXRT $49.00
- MDXG $12.00
- AVG Volume (30 Days)
- NXRT 94.3K
- MDXG 617.6K
- Earning Date
- NXRT 02-25-2025
- MDXG 02-26-2025
- Dividend Yield
- NXRT 5.26%
- MDXG N/A
- EPS Growth
- NXRT 54.64
- MDXG N/A
- EPS
- NXRT 1.77
- MDXG 0.52
- Revenue
- NXRT $264,974,000.00
- MDXG $342,804,000.00
- Revenue This Year
- NXRT N/A
- MDXG $9.56
- Revenue Next Year
- NXRT $0.18
- MDXG $9.19
- P/E Ratio
- NXRT $21.99
- MDXG $16.49
- Revenue Growth
- NXRT N/A
- MDXG 10.93
- 52 Week Low
- NXRT $28.20
- MDXG $5.47
- 52 Week High
- NXRT $48.37
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- NXRT 44.44
- MDXG 41.31
- Support Level
- NXRT $38.50
- MDXG $8.29
- Resistance Level
- NXRT $40.04
- MDXG $9.30
- Average True Range (ATR)
- NXRT 0.93
- MDXG 0.30
- MACD
- NXRT 0.25
- MDXG -0.04
- Stochastic Oscillator
- NXRT 62.96
- MDXG 27.10
About NXRT NexPoint Residential Trust Inc.
NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.